Fulcrum Therapeutics, Inc. Common Stock

Johnson Fistel is investigating Fulcrum Therapeutics for potential federal securities law violations following the company's June 1, 2026 announcement to discontinue its lead sickle cell drug pociredir due to FDA concerns about PRC2 complex targeting therapies carrying malignancy risks. The disclosure caused a sharp stock price decline, prompting...

Fulcrum Therapeutics (NASDAQ: FULC) shares plunged 49.69% in after-hours trading after announcing the discontinuation of pociredir, its lead experimental drug for sickle cell disease, due to FDA concerns about cancer-related risks associated with PRC2 pathway targeting drugs. The company launched a strategic review process to explore merger, acqu...

Fulcrum Therapeutics reported positive clinical data for pociredir showing robust fetal hemoglobin induction and improvements in hemolysis markers in sickle cell disease patients. The company plans to initiate a registration-enabling trial in H2 2026 and ended Q1 with $333.3 million in cash, providing runway into 2029. CFO Alan Musso will retire ...

MedicAlert Foundation, the Sickle Cell Disease Association of America (SCDAA), and Fulcrum Therapeutics announced a three-year partnership to improve emergency department care for sickle cell disease patients. The collaboration provides participants with MedicAlert Smart Medical ID Cards linked to secure digital health profiles containing physici...

Fulcrum Therapeutics reported positive 12-week data from the 20 mg dose cohort of its Phase 1b PIONEER trial of pociredir for sickle cell disease. The drug demonstrated robust fetal hemoglobin (HbF) induction with mean absolute HbF increasing by 12.2% (from 7.1% to 19.3%), 58% of patients achieving HbF levels ≥20%, and 58% reporting zero vaso-o...